The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&A ExpertiseNORFOLK, Va.--(BUSINESS WIRE)--ReAlta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback